Geneva Mid Cap Growth Managed Account
High-Quality Mid Cap Growth Equities
Jump to a section
Overview
Client Commitment
The strategy engages in bottom-up fundamental analysis to identify high-quality growth companies. The team believes investing in such proven, high-quality companies leads to competitive returns with below average risk over a market cycle.
Why Invest in the Portfolio
- The investment team utilizes a multifaceted approach which includes a bottom-up qualitative and quantitative assessment, supported by our top-down economic and investment outlook.
- Rather than operating as a star system in which one portfolio manager has final say, the team operates by consensus with all investment decisions being discussed as a team, while final decision-making responsibilities lie with the portfolio managers.
- Will not capitulate to transient market themes.
Concentrated, high-conviction portfolio with long-term growth focus
Experienced team with time-tested investment philosophy
Durability of concept
Portfolio Management
Performance
RETURNS
| Inception: Jan 01, 2005 | 3M | YTD | 1YR | 3YR | 5YR | 10YR | Since Inception |
|---|---|---|---|---|---|---|---|
| Composite Pure Gross* | 16.60% | 16.60% | 9.36% | 13.66% | 10.28% | 16.56% | 10.46% |
| Composite Net | 15.76% | 15.76% | 6.13% | 10.32% | 7.04% | 13.16% | 7.21% |
| Russell MidCap® Growth Index | 19.62% | 19.62% | 11.51% | 15.06% | 10.89% | 17.60% | 9.75% |
| Inception: Jan 01, 2005 | 3M | YTD | 1YR | 3YR | 5YR | 10YR | Since Inception |
|---|---|---|---|---|---|---|---|
| Composite Pure Gross* | 13.36% | 22.32% | 15.98% | 15.32% | 12.07% | 15.78% | 10.76% |
| Composite Net | 12.54% | 21.15% | 12.56% | 11.94% | 8.77% | 12.39% | 7.51% |
| Russell MidCap® Growth Index | 12.12% | 25.00% | 17.64% | 16.78% | 12.20% | 16.56% | 10.03% |
Past performance cannot guarantee future results. Investing involves risk, including the possible loss of principal and fluctuation of value. Returns greater than one year are annualized. Returns are expressed in U.S. dollars. All returns reflect the reinvestment of dividends and other earnings.
*Pure gross performance results do not reflect the deduction of any trading costs, fees or expenses and returns will be reduced by such advisory fee and other contractual expenses as described in the individual contract and Form ADV Part 2A. Pure gross returns are supplemental to net returns.
Net returns are calculated by subtracting the highest applicable Managed Account fee (3.00% annually, or 0.25% monthly) from the pure gross composite return. The Managed Account fee includes all charges for trading costs, portfolio management, custody and other administrative fees. Actual fees may vary depending on, among other things, the applicable fee schedule and portfolio size. The fees are available on request and may be found in Form ADV Part 2A.
*Pure gross performance results do not reflect the deduction of any trading costs, fees or expenses and returns will be reduced by such advisory fee and other contractual expenses as described in the individual contract and Form ADV Part 2A. Pure gross returns are supplemental to net returns.
Net returns are calculated by subtracting the highest applicable Managed Account fee (3.00% annually, or 0.25% monthly) from the pure gross composite return. The Managed Account fee includes all charges for trading costs, portfolio management, custody and other administrative fees. Actual fees may vary depending on, among other things, the applicable fee schedule and portfolio size. The fees are available on request and may be found in Form ADV Part 2A.
Commentary & Literature
1Q19 Portfolio Commentary Highlights
- The Portfolio underperformed its benchmark.
- Abiomed, Ligand Pharmaceuticals and Burlington Stores were our largest detractors.
- CoStar Group, Intuit and SS&C Technologies were our top three contributors.
- We are bullish on U.S. equities and believe companies have the ability to grow organically; however, we are closely monitoring the downside risks.